Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 1/2010

01-02-2010 | Clinical Trial Report

Darusentan in Resistant Hypertension: Lost in Translation

Authors: Frank Enseleit, Frank Ruschitzka

Published in: Current Hypertension Reports | Issue 1/2010

Login to get access

Excerpt

Weber MA, Black H, Bakris G, et al.: A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet 2009, 374(9699):1423–1431. …
Literature
1.
Mancia G, De Backer G, Dominiczak A, et al.: 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007, 28(12):1462–1536.PubMed
2.
Hypertension: uncontrolled and conquering the world [editorial]. Lancet 2007, 370(9587):539.
3.
Enseleit F, Luscher TF, Ruschitzka F: Darusentan: a new perspective for treatment of resistant hypertension? Expert Opin Investig Drugs 2008, 17(8):1255–1263.CrossRefPubMed
4.
Schrader J, Tebbe U, Borries M, et al.: [Plasma endothelin in normal probands and patients with nephrologic–rheumatologic and cardiovascular diseases]. Klin Wochenschr 1990, 68(15):774–779.CrossRefPubMed
5.
Saito Y, Nakao K, Mukoyama M, Imura H: Increased plasma endothelin level in patients with essential hypertension. N Engl J Med 1990, 322(3):205.PubMed
6.
Krum H, Viskoper RJ, Lacourciere Y, et al.: The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension. Bosentan Hypertension Investigators. N Engl J Med 1998, 338(12):784–790.CrossRefPubMed
7.
Nakov R, Pfarr E, Eberle S: Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension. Am J Hypertens 2002, 15(7 Pt 1):583–589.CrossRefPubMed
8.
Black HR, Bakris GL, Weber MA, et al.: Efficacy and safety of darusentan in patients with resistant hypertension: results from a randomized, double-blind, placebo-controlled dose-ranging study. J Clin Hypertens (Greenwich) 2007, 9(10):760–769.CrossRef
9.
Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ: The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008, 153(6):1105–1119.CrossRefPubMed
10.
Spieker LE, Mitrovic V, Noll G, et al.: Acute hemodynamic and neurohumoral effects of selective ET(A) receptor blockade in patients with congestive heart failure. ET 003 Investigators. J Am Coll Cardiol 2000, 35(7):1745–1752.CrossRefPubMed
11.
Luscher TF, Enseleit F, Pacher R, et al.: Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT). Circulation 2002, 106(21):2666–2672.CrossRefPubMed
12.
Anand I, McMurray J, Cohn JN, et al.: Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial. Lancet 2004, 364(9431):347–354.CrossRefPubMed
13.
Second pivotal phase III study of Gilead’s darusentan for resistant hypertension misses primary endpoints [press release]. Foster City, CA: Gilead Sciences, Inc; December 14, 2009. Available at http://​www.​gilead.​com/​pr_​1365747. Accessed December 17, 2009.
Metadata
Title
Darusentan in Resistant Hypertension: Lost in Translation
Authors
Frank Enseleit
Frank Ruschitzka
Publication date
01-02-2010
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 1/2010
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-009-0081-y

Other articles of this Issue 1/2010

Current Hypertension Reports 1/2010 Go to the issue

OriginalPaper

Renal Sympathetic Nerve Ablation: The New Frontier in the Treatment of Hypertension

OriginalPaper

Recent Advances in Genetics of the Spontaneously Hypertensive Rat

OriginalPaper

Anti-VEGF Therapies and Blood Pressure: More Than Meets the Eye

EditorialNotes

Literature Alert

OriginalPaper

Chronic Psychosocial Stress and Hypertension

OriginalPaper

Genome-Wide Association Studies: Contribution of Genomics to Understanding Blood Pressure and Essential Hypertension
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits